SecBot SecBot
8-K ·Filed Nov 5, 2026

PROF

Profound Medical Corp.
BEARISH
Impact 5/10
Horizonweeks Processed11d 7h ago SEC0001171843-26-007182
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue miss versus consensus is the primary negative, though the 86% YoY growth and improving cash burn trajectory are positive. Watch for the RSNA 2026 CAPTAIN data presentation (Nov 29-Dec 3) and any updates on the Cook Medical distribution ramp and Siemens Healthineers co-marketing progress.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$7.21
T+0 close · Nov 5, 2026 · via day close
Latest settled
+2.91%
T+5 · $7.42
Vs SPY
+0.32%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $7.21entry
  2. T+1 · 8d ago +1.80%α −0.56% · $7.34
  3. T+5 · 4d ago +2.91%α +0.32% · $7.42
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical reported Q3 2026 revenue of $9.8M (+86% YoY), well below the $13.8M consensus, with a GAAP net loss of $0.21 per share versus the $-0.20 consensus estimate. The company guided full-year 2026 revenue to at least $25.0M, announced a Cook Medical distribution agreement, and disclosed a planned CEO succession.

Key Financial Metrics

EPS
−$0.21
est −$0.20 · -5.0%
Revenue
$9.8M
est $13.8M · -28.8% · +85.9% YoY
Rating
miss
Guidance
at least $25.0M
maintained
Gross Margin
78.1%

Key Facts

  • Q3 2026 total revenue $9.8M, up 86% YoY from $5.3M, but below the $13.8M consensus estimate
  • GAAP net loss per share $0.21 vs consensus estimate of $-0.20 (miss)
  • Gross margin expanded to 78% from 74% in the prior-year period
  • Cash used in operating activities was $5.0M in Q3, down 56% sequentially from $11.3M in Q2
  • Full-year 2026 revenue guidance of at least $25.0M; gross margin guidance of 70% or higher
  • TULSA-PRO installed base grew to 98 systems; 5,000th procedure performed in October
  • Entered into a supply and distribution agreement with Cook Medical for U.S. distribution
  • CEO Arun Menawat to transition to Executive Chairman; Richard Fabian to become CEO effective January 14, 2027
  • Matthew Sobczyk appointed permanent CFO; Jason Mills joined the Board
  • Cash balance of $33.3M at September 30, 2026

Financial Impact

Revenue of $9.8M missed the $13.8M consensus by $4.0M (29% shortfall); EPS of $-0.21 missed the $-0.20 consensus by $0.01

revenueepscash flowgross margin

Segment Breakdown

SegmentRevenueGrowth
Recurring - non-capital$4.1M+1.0%
Capital equipment$5.7M+368.0%

Risk Factors

  • Revenue significantly below consensus despite strong YoY growth, indicating Street expectations may have been too high
  • Company remains pre-profitable with an accumulated deficit of $312M and operating cash burn of $24.9M year-to-date
  • CEO transition introduces execution risk during a critical commercial scaling phase
  • Full-year guidance of at least $25.0M implies Q4 revenue of at least $7.35M, which would be a sequential decline from Q3's $9.8M

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-007182
Document: f8k_110526.htm0001171843-26-007182
Document: 0001171843-26-007182-index-headers.html0001171843-26-007182
Document: 0001171843-26-007182-index.html0001171843-26-007182
Document: 0001171843-26-007182.txt0001171843-26-007182
8-K Data (Synthetic)0001171843-26-007182

Track record

22 reports on PROF

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +25.61% at T+60 after the Mar 5, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $7.44 Now $7.34 −1.34% settles Dec 11
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $7.34 Now $7.34 +0.00% settles Dec 8
  3. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $7.21 Now $7.34 −1.80% settles Dec 7
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $7.16 Now $7.34 +2.51% settles Dec 3
  5. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $6.57 Now $7.34 +11.72% settles Nov 30
  6. Oct 22, 202625d ago 8-K Neutral 2/10 Entry $5.56 Now $7.34 +32.01% settles Nov 20
  7. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $6.62 to $7.68 Now $7.34 +10.88% ▲ +16.01% +18.57% vs SPY
  8. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $6.90 to $7.01 Now $7.34 +6.38% ▲ +1.59% +7.15% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 7/10 Entry $6.91 to $7.16 Now $7.34 +6.22% ▲ +3.62% +8.91% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 2/10 Entry $6.89 to $6.03 Now $7.34 +6.53% ▼ −12.48% −13.08% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026